Pharma Pulse 1/20/25: Leveraging Data Standards, The Good and Bad News About Melanoma & more

2025 Trends: Leveraging Data Standards

Kimberly Tableman, founder & CEO, ESPERO, discussed the challenges and trends in protocol development for clinical trials. She also highlighted technological advancements, such as data interoperability standards like ICH M11 and CDISC, and how they are expected to streamline protocol development and support generative AI in 2025.

The Good and Bad News About Melanoma

Five-year survival rates improved greatly because of immunotherapy and other advances, according to the American Cancer Society's annual report on cancer incidence and mortality. But there is a wide gap between how well White patients fare compared to Black patients.

Take our State of the Industry Survey!

Biden Issues 11th-Hour Cyber Executive Order

Brandishing $102 billion in I.T. purchasing power, the U.S. will require tech firms that want government contracts to meet higher security standards, the White House says.

Second Round of Medicare Drug Price Controls Perpetuates Flawed, Harmful Policy

The Centers for Medicare and Medicaid Services’ (CMS) announcement of 15 new drugs to be subject to price controls under the Inflation Reduction Act (IRA) represents the continuation of a flawed federal policy that has failed to achieve its stated goals and is causing significant health and economic harm.

Debra Harris on LinkedIn

With challenges like physician shortages and growing patient demand for convenience, it's so important to recognize the critical role pharma can play (and increasingly is playing) in improving access, removing barriers to care and helping to create a better patient experience. In this Pharmaceutical Executive article, our CEO Pouria Sanae shares his thoughts. At ixlayer we’re proud to lead this transformation, bridging the gap between patients, providers, and the healthcare ecosystem.

#PharmaInnovation #HealthTech #PatientCare

Have news you want us to share in Pharma Pulse? Reach out to Editor Miranda Schmalfuhs